Precision Biosciences vs Entrada Therapeutics
Precision Biosciences reported revenue of $34 million in fiscal 2025, 1.4 times Entrada Therapeutics' $25 million in fiscal 2025. Precision Biosciences' revenue fell 50.1% in its latest year, and Entrada Therapeutics' fell 87.9%. Precision Biosciences had an operating margin of -152.2%, against -621.1% at Entrada Therapeutics. Free cash flow was −$66 million at Precision Biosciences and −$130 million at Entrada Therapeutics.
Side by side
| Precision Biosciences | Entrada Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $34M | $25M |
| Revenue growth | −50.1% | −87.9% |
| Revenue growth a year, last 5 years | 7.1% | — |
| Gross margin | — | — |
| Operating margin | −152.2% | −621.1% |
| Net margin | −133.4% | −565.5% |
| Free cash flow | −$66M | −$130M |
| Free cash flow margin | −192.4% | −509.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 86.3% | 6.1% |
| Last close | $6.91 | $4.64 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $63,215, sold $412,359 | bought $291,124, sold $6.7 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Precision BiosciencesEntrada Therapeutics
Operating margin
Percent of revenue
Precision BiosciencesEntrada Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Precision BiosciencesEntrada Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Precision Biosciences and Entrada Therapeutics pages.